Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation?
Stroke 32:2828-2832, Evans,A.,et al, 2001
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction
Stroke 54:1954-1959, Bilski.A.,et al, 2023
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Lambls Excrescense Associated with Cryptogenic Stroke
Am J Case Rep 16:876-881, Chu, A.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Aspirin for Acute Stroke of Unknown Etiology in Resourse-Limited Settings
Neurol 83:787-793, Berkowitz, A.L.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
NEJM 367:817-825, The SPS3 Investigators, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease
Stroke 42:e420-e463, Brott, T.G.,et al, 2011
Intracranial Atherosclerotic Disease: An Update
Ann Neurol 66:730-738, Qureshi,A.,et al, 2009
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Sports-Related Internal Carotid Artery Dissection: Pathogenesis and Therapeutic Point of View
The Neurologist 14:307-311, Dharmasaroja,P. &Dharmasaroja,P., 2008
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Intracerebral Hemorrhage
The Neurologist 11:311-324, Badjatia,N. &Rosand,J., 2005
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Should I Start All My Ischaemic Stroke and TIA Patients on a Statin, an ACE Inhibitor, a Diuretic, and Aspirin Today?
JNNP 74:1461-1464, Sandercock,P.A.G., 2003
Early Lacunar Strokes Complicating Polyarteritis Nodosa
Neurol 54:883-889, Reichhart,M.D.,et al, 2000
Susac Syndrome
Medicine 77:3-11, Papo,T.,et al, 1998
Stroke and Transient Ischaemic Attacks
JNNP 57:534-543, Humphrey,P., 1994
Medical Treatment for Stroke Prevention
Ann Int Med 121:41-55, Matchar,D.B.,et al, 1994
Antiphospholipid Antibodies in Cerebral Ischemia
Stroke 22:750-753, Montalban,J.,et al, 1991
Intracranial Branch Atheromatous Disease:A Neglected, Understudied, and Underused Concept
Neurol 39:1246-1250, Caplan,L.R., 1989
Cortical Superficial Siderosis and Transient Focal Neurological Episode Preceding Lobar Hemorrhage in Cerebral Amyloid Angiopathy
Stroke 54:e48-e51, Therdorou,A.,et al, 2023
Antithrombotic Therapy in Patients with Cerebral Microbleeds or Cortical Siderosis, Is This Contraindicated?
Neurol 100:551-552, Schneck,M.J., &Biller,J., 2023
Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023
Coagulation Factor Expression and Composition of Arterial Thrombi in Cancer-Associated Stroke
Stroke 54:2981-2989, Yoo,J.,et al, 2023
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Cerebral Microbleeds
Stroke 52:2347-2355, Graff-Radford, J.,et al, 2021
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection
JAMA Neurol 76:657-664, Markus, H.S.,et al, 2019